In this clinical study, we aimed to measure plasma sLRP1, CyPA, and MMP9 levels in patients with AD, patients with VaD, and healthy controls and to evaluate their correlation with cognitive function to assist the discovery of new biomarkers. The gene discussed is MMP9; the disease is Alzheimer disease.